Novartis cuts anti-malaria drug cost

Pharmaceutical company Novartis is cutting the price of its anti-malarial drug Coartem by 20 per cent.

This content was published on April 23, 2008 - 08:54

The reduced price to the public will come into effect on World Malaria Day on Friday, the company announced on Wednesday.

Novartis said the move was made possible through efficiency gains after expanding its production capacity in the United States and China.

The drug is currently supplied to the public at cost under an agreement with the World Health Organisation. The reduction will apply to all Coartem dosages, reducing the average cost from $1 (SFr1.01) to $0.80.

Novartis says Coartem can produce a cure rate of up to 95 per cent and has been used to help save about 450,000 lives.

Currently, the most effective drugs against the disease are combination treatments such as Coartem containing artemisinin, a plant derivative used in traditional Chinese medicine to treat fever.

Articles in this story

In compliance with the JTI standards

In compliance with the JTI standards

More: SWI certified by the Journalism Trust Initiative

You can find an overview of ongoing debates with our journalists here. Please join us!

If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at

Sort by

Change your password

Do you really want to delete your profile?

Your subscription could not be saved. Please try again.
Almost finished... We need to confirm your email address. To complete the subscription process, please click the link in the email we just sent you.

Discover our weekly must-reads for free!

Sign up to get our top stories straight into your mailbox.

The SBC Privacy Policy provides additional information on how your data is processed.